Welcome to our dedicated page for MOLECULAR PARTNERS SEC filings (Ticker: MOLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Molecular Partners’ SEC disclosures can feel like wading through lab notebooks and legal code at the same time. Clinical-stage biotech filings run deep with trial data, milestone payments, and future financing clauses that influence cash runway. If you have ever searched for “Molecular Partners insider trading Form 4 transactions” or wondered how a 300-page annual report links DARPin pipeline progress to dilution risk, you know the challenge.
Stock Titan solves that problem. Our AI reads every 10-K, 10-Q and 8-K—plus the company’s 20-F equivalents—line by line, then delivers concise explanations in plain language. Need the latest “Molecular Partners quarterly earnings report 10-Q filing”? It is here, with side-by-side AI commentary on R&D spending trends. Looking for “Molecular Partners Form 4 insider transactions real-time” or alerts on option grants? You will receive them moments after they hit EDGAR. Our platform also ties each disclosure to what matters for a DARPin pipeline: clinical trial milestones in an 8-K, royalty details in a collaboration exhibit, or governance updates inside the “Molecular Partners proxy statement executive compensation.”
Because biotech moves quickly, we update continuously and surface practical insights investors act on: monitor executive stock transactions Form 4, compare cash burn across quarters, or scan an “Molecular Partners annual report 10-K simplified” summary before a funding round. For deeper context, select any headline to see “understanding Molecular Partners SEC documents with AI,” where complex passages are annotated, key figures highlighted, and “Molecular Partners 8-K material events explained” in one click. Spend less time decoding filings and more time deciding whether DARPin science—and the balance sheet behind it—fits your investment thesis.
Molecular Partners AG furnished a press release and unaudited condensed interim financials for the three and nine months ended September 30, 2025. The company reported a net loss of CHF 49,002 thousand for the nine-month period and CHF 11,836 thousand for the quarter. Revenues were nil after prior-period collaboration income ended, while operating expenses totaled CHF 45,502 thousand year-to-date, including a CHF 2,733 thousand restructuring charge tied to a June 2025 efficiency initiative.
Research and development expense was CHF 30,954 thousand and selling, general and administrative expense was CHF 11,815 thousand for the nine months. Basic and diluted net result per share was CHF (1.32) year-to-date and CHF (0.33) in the quarter. Cash and cash equivalents were CHF 82,359 thousand with short-term time deposits of CHF 22,162 thousand as of September 30, 2025. Net cash used in operating activities was CHF 40,106 thousand for the nine months, partly offset by movements in time deposits, leading to a period-end cash balance increase from January 1.
Total shareholders’ equity was CHF 95,529 thousand at quarter-end. Collaboration with Novartis ended in 2024, and the company recorded no revenue from that agreement in 2025.
Molecular Partners (MOLN) reported H1 2025 results showing continued investment in its DARPin drug platform and a solid cash runway. The company has CHF 114.5 million in cash and short-term deposits as of June 30, 2025 and expects to be funded into 2028 excluding potential partner receipts. In H1 2025 it used CHF 30.2 million in operating cash, recorded an operating loss of CHF 33.5 million and a net loss of CHF 37.2 million, and recognized CHF 2.6 million of restructuring expenses. Development highlights include a co-development with Orano Med on 212Pb Radio-DARPin candidates MP0712 (DLL3) and MP0726 (MSLN), positive preclinical MP0712 data presented at AACR 2025, ongoing FDA dialogue with an IND filing for MP0712 expected in Q3 2025 and first-in-human dosing planned in 2025 pending clearance, with initial clinical data expected in H1 2026. H1 2025 financial statements are available on the company's website.
Molecular Partners AG has filed an S-8 registration statement to register securities related to three employee benefit plans: Performance Share Plan 2025 for Employees, Performance Share Plan 2025 for Management, and Restricted Share Plan 2025.
Key details of the filing:
- Filed on June 25, 2025 for Swiss-based biotech company trading under symbol MOLN
- Registration covers three distinct employee benefit plans introduced in 2025
- Company maintains principal executive offices in Zurich-Schlieren, Switzerland with U.S. presence in Cambridge, Massachusetts
- Filing incorporates by reference the company's annual report on Form 20-F for FY2024 and recent Form 6-K reports
The registration is signed by CEO Patrick Amstutz and includes signatures from the full board of directors, including Chairman William Burns. The company has appointed legal representation from Cooley LLP (US) and Homburger AG (Switzerland) for this filing. This registration enables Molecular Partners to offer equity-based compensation to both employees and management under these newly established plans.
FAQ
What is the current stock price of MOLECULAR PARTNERS (MOLN)?
What is the market cap of MOLECULAR PARTNERS (MOLN)?
